Pulmonx (NASDAQ:LUNG) and Biotricity (NASDAQ:BTCY) Head-To-Head Survey

Biotricity (NASDAQ:BTCY) and Pulmonx (NASDAQ:LUNG) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, profitability, earnings, risk, analyst recommendations, institutional ownership and dividends.

Profitability

This table compares Biotricity and Pulmonx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biotricity	-97.05%	N/A	-221.26%
Pulmonx	-72.01%	-53.88%	-33.47%

Institutional and Insider Ownership

3.9% of Biotricity shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 10.1% of Biotricity shares are owned by insiders. Comparatively, 5.7% of Pulmonx shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Risk and Volatility

Biotricity has a beta of 1.08, meaning that its share price is 8% more volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.66, meaning that its share price is 34% less volatile than the S&P 500.

Earnings & Valuation

This table compares Biotricity and Pulmonx”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biotricity	$12.06 million	0.71	-$14.09 million	($1.37)	-0.26
Pulmonx	$68.68 million	3.56	-$60.84 million	($1.47)	-4.21

Biotricity has higher earnings, but lower revenue than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than Biotricity, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a breakdown of current ratings and price targets for Biotricity and Pulmonx, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biotricity	0	1	0	0	2.00
Pulmonx	0	2	4	0	2.67

Pulmonx has a consensus price target of $12.75, indicating a potential upside of 105.98%. Given Pulmonx’s stronger consensus rating and higher possible upside, analysts plainly believe Pulmonx is more favorable than Biotricity.

Summary

Pulmonx beats Biotricity on 8 of the 14 factors compared between the two stocks.

About Biotricity

Biotricity, Inc., a medical technology company, provides biometric data monitoring solutions in the United States. The company focuses on delivery of remote monitoring solutions to medical, healthcare, and consumer markets, including diagnostic and post-diagnostic solutions for lifestyle and chronic illnesses. It offers Bioflux mobile cardiac telemetry solution, an integrated ECG device; and ECG analysis software that analyzes and synthesizes patient ECG monitoring data, as well as software components. The company is based in Redwood City, California.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.